삼진제약

005500KOSPI의약품 제조업

65.1 / 100

Reference Date: 2026-06-10

Financial Score27.0 / 40

News Sentiment20.1 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but Revenue metrics are weak. Slightly up 4.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Samjin Pharmaceutical operates a diverse portfolio spanning OTC drugs, specialty pharmaceuticals, and APIs, leveraging its competitive edge in the pharmaceutical market. The company focuses on developing innovative treatments for age-related diseases and metabolic disorders, with key products including the anticoagulant 'Plaeris' and analgesic 'Geborin'. It is expanding into health foods and medical devices, and has enhanced its global production capabilities through the 2022 completion of its Osong facility.

Number of Employees

819people

Average Salary

81.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

9.78Industry Average 11.935.0Point

In line with industry avg

PBR

0.88Industry Average 0.894.0Point

In line with industry avg

ROE

8.76Industry Average 4.017.0Point

2.2x industry avg (excellent)

Debt Ratio

11.36Industry Average 12.434.0Point

In line with industry avg

Trend 2023~20257.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲2.9% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲19.6% (2-year basis)

ROE Trend

3.5 / 4

Avg ROE 10.2% (improving, 3yr)

Detailed News Sentiment

20 totalPositive 18Neutral 2Negative 0Average Sentiment Score 80.5

Positive
[클리니컬 히스토리] 삼진제약, 아리바이오 2차 베팅…치매 다음은 백....
삼진제약이 아리바이오와의 협력을 치매 치료제에서 백신으로 확장함으로써 새로운 성장 동력을 모색하고 있다.
Positive
삼진제약, 저함량 알츠하이머 치매 치료제 출시
삼진제약의 저함량 알츠하이머 치료제 출시로 인해 긍정적인 시장 반응 예상.
Positive
삼진제약, 저용량 치매 치료제 ‘뉴토인 3㎎’ 출시
삼진제약의 저용량 치매 치료제 출시로 알츠하이머 환자 치료 접근성이 향상되었다.

Detailed Momentum

52-week position3.0Point

52w lower range (26%)

Current 19,200Won52-week high 24,70052-week low 17,240

1-month return4.0Point

1m +4.35% (slight rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-06-02
Neutral기업지배구조보고서공시2026-06-01
Neutral[기재정정]주식등의대량보유상황보고서(약식)2026-05-28
Neutral주식등의대량보유상황보고서(약식)2026-05-22
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-21